CRA was retained by a Fortune 100 pharmaceutical company to assess the multi-year selection process associated with a recent acquisition. Working with the client CRA developed analyses to examine the impact decisions commonly associated with blending companies. The analyses incorporated different selection processes for areas of overlap, merger required spin-offs, as well as general workforce adjustments. CRA’s analyses provided a “real-time” review of the decisions as they were being made to address particular areas of risk.
When simple data patterns are not enough: The economic complexity behind non-competes in the healthcare industry
The Federal Trade Commission (FTC), Department of Justice (DOJ), and state regulators have publicly stated that non-compete agreements (NCAs) are an...